Medarex raises $359 million

MEDX, a developer of monoclonal antibody-based therapeutics, sold 2.1 million shares at $172 per share. The follow-on is being underwritten by Morgan Stanley Dean Witter; Chase H&Q; Dain Rauscher Wess...